BioIntel | Independent Biotech Intelligence

Wainua Phase 3 Setback Clouds TTR Silencers, Strengthening The Case For ATTR-CM Stabilizers

Jonathan BlakeAug 29, 2026

Nature Papers Detail Two Prime Editing Routes For Large DNA Insertions Without Double-Strand Breaks

Michael TorresAug 29, 2026

AusperBio Raises $120 Million Series C To Push AHB-137 Through Phase 3 In Chronic Hepatitis B

Sophia ReynoldsAug 29, 2026

Featured

BioNTech And Genentech Halt BNT122 Phase 2 After More Deaths In Vaccine Arm, Narrowing The Monotherapy Case In Colorectal Cancer

BioNTech and Genentech terminated a phase 2 study of autogene cevumeran in surgically removed stage 2 or 3 colorectal cancer after an independent Data Safety Monitoring Board identified a numerical imbalance in overall survival. The outcome weakens the case for personalized mRNA cancer vaccines as monotherapy in immunotherapy-insensitive tumors while leaving combination studies intact.

Dr. Priya NandakumarAug 29, 2026

Read featured

ALL INTELLIGENCE

Biopharmaceutical Industry

BioNTech And Genentech Halt BNT122 Phase 2 After More Deaths In Vaccine Arm, Narrowing The Monotherapy Case In Colorectal Cancer

Dr. Priya NandakumarAug 29, 20262 min

Biopharmaceutical Industry

Wainua Phase 3 Setback Clouds TTR Silencers, Strengthening The Case For ATTR-CM Stabilizers

New figures from AstraZeneca and Ionis’ failed Phase 3 ATTR-CM study make the miss look worse than many expected. The readout shifts attention back toward oral stabilizers and raises new questions about combination use of TTR silencers.

Jonathan BlakeAug 29, 20262 min

Biotech Innovation

Nature Papers Detail Two Prime Editing Routes For Large DNA Insertions Without Double-Strand Breaks

Two Nature Biotechnology papers describe distinct prime editing approaches for inserting or replacing larger DNA fragments without generating double-strand breaks. Together, they point to a maturing effort to expand precise genome engineering beyond point edits and short indels.

Michael TorresAug 29, 20263 min

Healthcare Investment

AusperBio Raises $120 Million Series C To Push AHB-137 Through Phase 3 In Chronic Hepatitis B

AusperBio has added $120 million in series C financing to advance its chronic hepatitis B oligonucleotide program, led by late-stage candidate AHB-137. The round gives the Bay Area biotech fresh capital to fund phase 3 work in China and extend its platform beyond a single asset.

Sophia ReynoldsAug 29, 20262 min

Regulatory & Policy

Juul Gets FDA Clearance For Juul2 With Optional Age Verification, Reopening Its U.S. Device Pipeline

Juul Labs received federal permission to sell Juul2, an updated e-cigarette with an optional app-based age-verification feature. The decision lets the company launch a new device and revised tobacco- and menthol-flavored cartridges after years of litigation, layoffs and market-share loss.

Dr. Priya NandakumarAug 29, 20262 min

Regulatory & Policy

Lilly Wins Mounjaro Cardiovascular Risk Approval, Matching Novo In A Key GLP-1 Market

The FDA approved Mounjaro to reduce cardiovascular risk in adults with type 2 diabetes at high risk for heart attack, stroke or cardiovascular death. The decision gives Eli Lilly a cardiovascular label in a market where Novo Nordisk had already established a lead with semaglutide.

Dr. Priya NandakumarAug 28, 20262 min

Biopharmaceutical Industry

Teva Sets $57.5 Million Floor For BioXcel Assets, Tying More Value To BXCL501 FDA Timing

BioXcel Therapeutics filed for Chapter 11 and named Teva Pharmaceuticals as stalking horse bidder for substantially all of its assets. The proposed deal sets a baseline value around a neuroscience portfolio centered on BXCL501, with milestone economics linked to the timing of a pending FDA decision.

Emily CarterAug 28, 20262 min

Biopharmaceutical Industry

AstraZeneca And Amgen Post Tezspire EoE Phase 3 Win, Opening A Dosing-Based Challenge To Dupixent

AstraZeneca and Amgen said Tezspire met Phase 3 goals in eosinophilic esophagitis, a market where Dupixent is the only approved biologic. The result extends Tezspire’s immunology expansion, but the competitive case still depends on data the companies have not yet disclosed.

Michael TorresAug 28, 20262 min

Healthcare Investment

Genentech Pays $45 Million Upfront For DualityBio ADCs, Targeting Post-Topoisomerase Resistance

Genentech agreed to pay DualityBio $45 million upfront in a deal worth more than $1 billion in potential milestones for ADC programs aimed at tumors that progress after existing topoisomerase-based drugs. The pact points to a new investment theme inside the crowded ADC field: designing for the resistance setting rather than only chasing new targets.

Dr. Alex MorganAug 28, 20262 min

Biopharmaceutical Industry

Roivant Wins Lisraya Approval In Dermatomyositis, Adding A Once-Daily Pill For A Rare Autoimmune Disease

The Food and Drug Administration approved Roivant and Priovant's brepocitinib for dermatomyositis. The decision gives patients a new oral option in a disease where high-dose steroids and other immune-suppressing drugs are the current standard of care.

Michael TorresAug 28, 20261 min

Regulatory & Policy

RFK Jr. Faces New Scrutiny Over Samoa Letters, Complicating Vaccine Policy Credibility

Newly obtained documents conflict with Robert F. Kennedy Jr.'s statements to lawmakers that his 2019 Samoa trip had nothing to do with vaccines. The dispute matters beyond the trip itself because it cuts into the trust basis on which some senators backed his confirmation.

Dr. Alex MorganAug 28, 20263 min

Join the BioIntel newsletter

ALL INTELLIGENCE